Regulation of the Nuclear Factor (NF)-κB Pathway by ISGylation

• Published in: Biological and Pharmaceutical Bulletin Vol. 31; no. 12; pp. 2223 - 2227
• Main Authors: Minakawa, Miki, Sone, Takayuki, Takeuchi, Tomoharu, Yokosawa, Hideyoshi
• Format: Journal Article
• Language: English
• Published: The Pharmaceutical Society of Japan 01.12.2008
• Subjects: interferon-stimulated gene; nuclear factor-κB; post-translational modification; tumor necrosis factor receptor-associated factor 6; ubiquitin-conjugating enzyme
• ISSN: 0918-6158; 1347-5215
• DOI: 10.1248/bpb.31.2223

Post-translational modification with ISG15 (interferon-stimulated gene 15 kDa) (ISGylation) is mediated by a sequential reaction similar to ubiquitination, and various target proteins for ISGylation have been identified. We previously reported that ISGylation of the E2 ubiquitin-conjugating enzyme Ubc13 suppresses its E2 activity. Ubc13 forms a heterodimer with Uev1A, a ubiquitin-conjugating enzyme variant, and the Ubc13–Uev1A complex catalyzes the assembly of a Lys63-linked polyubiquitin chain, which plays a non-proteolytic role in the nuclear factor (NF)-κB pathway. In this study, we examined the effect of ISGylation on tumor necrosis factor receptor-associated factor (TRAF)-6/transforming growth factor β-activated kinase (TAK)-1-dependent NF-κB activation. We found that expression of the ISGylation system suppresses NF-κB activation via TRAF6 and TAK1 and that the level of polyubiquitinated TRAF6 is reduced by expression of the ISGylation system. Taken together, the results suggest that the NF-κB pathway is negatively regulated by ISGylation.